Medically reviewed by Steffini Stalos, DO Hemophilia disease is a rare inherited bleeding disorder. People with this genetic ...

Treatment involved an antithrombin-based dose regimen targeting antithrombin levels between 15% and 35%, starting at 50 mg once every 2 months, individually adjusted to 20, 50, or 80 mg monthly or 20 ...

Rising Prevalence of Hemophilia, Increasing Adoption of Recombinant Therapies, and Breakthroughs in Gene Therapy Propel Market Growth.Pune, March 12, 2025 (GLOBE NEWSWIRE) -- Hemophilia Market Size & ...

Hemophilia B is an X-linked recessive hemorrhagic disorder caused by a deficiency or abnormality of clotting factor IX. Human factor IX is a vitamin-K-dependent multidomain glycoprotein composed ...

“Gene therapy for hemophilia A with the use of lentiviral vector-transduced autologous HSCs resulted in stable factor VIII ...

EMERYVILLE, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company ...

Market Valuation Set to Surge from USD 13.23 Billion in 2024 at a CAGR of 5.69% ...

Hemophilia A is a disorder that makes a person predisposed to bleeding. This can cause issues ranging from prolonged bleeding from a minor wound to bleeding emergencies. The condition is caused by ...

People with hemophilia A bleed and bruise easily, and their blood takes a long time to form clots. Hemophilia A is a rare, serious condition that has no cure, but is treatable. Hemophilia A is ...

Weak demand for Pfizer’s hemophilia gene therapy Beqvez has led the pharmaceutical company to “cease further development and commercialization” of the one-time treatment, a Pfizer spokesperson ...

The U.K.'s NICE recommended Altuvoct be available through the National Health Service (NHS) as a treatment for severe ...